Trial Profile
Proleukin(R) Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jun 2019
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary)
- Indications Malignant melanoma; Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms PROCLAIM
- Sponsors Prometheus Laboratories
- 11 Jun 2019 Status changed from recruiting to completed.
- 05 Jun 2018 Results assessing survival (n=939) were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2017 Results (n=1457) assessing association of overall survival and tumor control with development of immune-related events in patients treated with IL2, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology